Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

November 29, 2022: MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference

MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference MaaT Pharma will…
Press Releases
November 8, 2022: MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
Press Releases
November 7, 2022: MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
Press Releases
November 3, 2022: MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Press Releases
October 7, 2022: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

See more

Media Coverage

Media

MedNous – FDA approves first faecal microbiota product

Hervé Affagard, CEO and co-founder of MaaT Pharma, commented on the first FDA-approval for a…
Media
Labiotech – FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field
Media
Labiotech – MaaT Pharma: leading the charge in microbiome therapeutics
Media
October 13, 2022: Replay of Microbiome session of the 2022 edition of HTID with Hervé Affagard
Media
October 12, 2022: Interview of Hervé Affagard in Lyon Décideurs – Bourses & Valeurs
Media
October 10, 2022: Interview of Hervé Affagard in La Bourse et la Vie

See more

Posters

Posters

Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program

Posters
Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033
Posters
Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes
Posters
EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics
Posters
ASH 2019: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics
Posters
An evaluation of binning methods to recover human gut microbial pan-genomes from non-redundant reference gene catalog

Videos

Videos

R&D Day 2022 replay

On June 7th, 2022, MaaT Pharma hosted its virtual R&D Day to share the latest…
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année
Videos
Hybridays 2021: Savita BERNAL, Chief Business Officer at MaaT Pharma